We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
- Authors
Gillison, Maura L; Blumenschein, George; Fayette, Jerome; Guigay, Joel; Colevas, A Dimitrios; Licitra, Lisa; Harrington, Kevin J; Kasper, Stefan; Vokes, Everett E; Even, Caroline; Worden, Francis; Saba, Nabil F; Docampo, Lara Carmen Iglesias; Haddad, Robert; Rordorf, Tamara; Kiyota, Naomi; Tahara, Makoto; Jayaprakash, Vijayvel; Wei, Li; Ferris, Robert L
- Abstract
In the randomized, phase 3 CheckMate 141 trial, nivolumab significantly improved overall survival (OS) versus investigator's choice (IC) of chemotherapy at primary analysis among 361 patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) post-platinum therapy. Nivolumab versus IC as first-line treatment also improved OS among patients with R/M SCCHN who progressed on platinum therapy for locally advanced disease in the adjuvant or primary setting at 1-year follow-up. In the present long-term follow-up analysis of patients receiving first-line treatment, OS benefit with nivolumab (n = 50) versus IC (n = 26) was maintained (median: 7.7 months versus 3.3 months; hazard ratio: 0.56; 95% confidence interval, 0.34-0.94) at 2 years. No new safety signals were identified. In summary, this long-term 2-year analysis of CheckMate 141 supports the use of nivolumab as a first-line treatment for patients with platinum-refractory R/M SCCHN.
- Subjects
EVALUATION of medical care; CONFIDENCE intervals; CANCER chemotherapy; HEAD &; neck cancer; METASTASIS; CANCER relapse; RANDOMIZED controlled trials; CANCER patients; TREATMENT effectiveness; NIVOLUMAB; STATISTICAL sampling; SQUAMOUS cell carcinoma; IMMUNOTHERAPY; PHARMACODYNAMICS
- Publication
Oncologist, 2022, Vol 27, Issue 2, pe194
- ISSN
1083-7159
- Publication type
Article
- DOI
10.1093/oncolo/oyab036